BioAge Labs’ (BIOA) “Buy” Rating Reiterated at Roth Capital

Roth Capital reiterated their buy rating on shares of BioAge Labs (NASDAQ:BIOA) in a report published on Wednesday morning,Benzinga reports. They currently have a $25.00 target price on the stock.

Other research analysts also recently issued reports about the company. Wall Street Zen downgraded BioAge Labs from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, July 21st. BTIG Research reissued a “buy” rating and issued a $40.00 target price on shares of BioAge Labs in a research note on Tuesday. Jefferies Financial Group set a $21.00 target price on shares of BioAge Labs in a report on Friday, July 31st. Finally, Needham & Company LLC dropped their price target on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $36.57.

BioAge Labs Price Performance

BioAge Labs stock opened at $8.49 on Wednesday. The firm has a 50-day moving average of $14.93 and a 200-day moving average of $17.45. BioAge Labs has a one year low of $4.68 and a one year high of $25.95. The company has a market cap of $389.69 million, a price-to-earnings ratio of -3.57 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%.The business had revenue of $2.45 million for the quarter. As a group, sell-side analysts expect that BioAge Labs will post -2.45 earnings per share for the current year.

Institutional Trading of BioAge Labs

Hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD boosted its holdings in shares of BioAge Labs by 24.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,808 shares of the company’s stock worth $196,000 after buying an additional 2,917 shares during the period. Barclays PLC raised its holdings in BioAge Labs by 9.3% in the 4th quarter. Barclays PLC now owns 37,780 shares of the company’s stock valued at $500,000 after acquiring an additional 3,222 shares during the period. Legal & General Group Plc bought a new position in BioAge Labs in the 2nd quarter valued at about $84,000. Bank of America Corp DE lifted its position in BioAge Labs by 46.3% during the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after acquiring an additional 3,517 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in BioAge Labs during the third quarter worth approximately $27,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.